Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2006;10(6):316.
doi: 10.1186/cc5071.

Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death

Sanjay Gupta  1 , Eric B Milbrandt, Lakshmipathi Chelluri
Affiliations
Comment

Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death

Sanjay Gupta et al. Crit Care. 2006.
No abstract available

PubMed Disclaimer

Comment on

  • Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
    Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Abraham E, et al. N Engl J Med. 2005 Sep 29;353(13):1332-41. doi: 10.1056/NEJMoa050935. N Engl J Med. 2005. PMID: 16192478 Clinical Trial.

References

    1. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353:1332–1341. doi: 10.1056/NEJMoa050935. - DOI - PubMed
    1. Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G, III, Kinasewitz GT. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost. 2003;90:642–653. - PubMed
    1. Siegel JP. Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med. 2002;347:1030–1034. doi: 10.1056/NEJMsb021512. - DOI - PubMed
    1. Baillie JK, Murray G. Drotrecogin alfa (activated) in severe sepsis. N Engl J Med. 2006;354:94–96. doi: 10.1056/NEJMc052759. - DOI - PubMed
    1. Friedrich JO. Drotrecogin alfa (activated) in severe sepsis. N Engl J Med. 2006;354:94–96. doi: 10.1056/NEJMc052759. - DOI - PubMed

LinkOut - more resources